title: [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer].
abstract: The aim of this study was to evaluate the efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (I-LV) in 50 patients with advanced or recurrent colorectal cancer in our institute. The dose of 5-FU was 600 mg/m2 and the dose of l-LV was 250 mg/m2. Objective response were 36.8% of patients who had administration of full-dose and 14.8% of patients who had the administration of reduced dose or prolonged interval. No significant difference was observed in clinical benefit rates between patients administrated in full-dose and patients in reduced dose or prolonged interval. Median survival time (MST) of patients in reduced dose or prolonged interval is longer than patients in full-dose. These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval.
authors.affiliation: Dept. of Clinical Oncology, Institute of Development, Aging and Cancer and Tohoku University Hospital, Tohoku University.
authors.forename: Natsuko
authors.initials: N
authors.lastname: Chiba
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshioka
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Kato
authors.forename: Shin
authors.initials: S
authors.lastname: Takahashi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Shibata
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kato
authors.forename: Masato
authors.initials: M
authors.lastname: Sakayori
authors.forename: Kazunori
authors.initials: K
authors.lastname: Otsuka
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kakudo
authors.forename: Hisatsugu
authors.initials: H
authors.lastname: Ohori
authors.forename: Gengo
authors.initials: G
authors.lastname: Yamaura
authors.forename: Masanobu
authors.initials: M
authors.lastname: Takahashi
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Yasuda
authors.forename: Chikashi
authors.initials: C
authors.lastname: Ishioka
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D007970:Leukopenia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D002955:Leucovorin; D005472:Fluorouracil